174 related articles for article (PubMed ID: 37272362)
1. Risk of Serious Infections in Patients with Bullous Pemphigoid: A Population-based Cohort Study.
Chang TH; Wu CY; Chang YT; Lyu YS; Wu CY
Acta Derm Venereol; 2023 Jun; 103():adv5329. PubMed ID: 37272362
[TBL] [Abstract][Full Text] [Related]
2. Association of bullous pemphigoid and comorbid health conditions: a case-control study.
Lee S; Rastogi S; Hsu DY; Nardone B; Silverberg JI
Arch Dermatol Res; 2021 Jul; 313(5):327-332. PubMed ID: 32647978
[TBL] [Abstract][Full Text] [Related]
3. Risk of bullous pemphigoid and pemphigus in patients on chronic dialysis: A nationwide population-based cohort study.
Tang CH; Sue YM; Chang CL; Wang CC
J Dermatol; 2023 Dec; 50(12):1568-1575. PubMed ID: 37665203
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.
Cugno M; Marzano AV; Bucciarelli P; Balice Y; Cianchini G; Quaglino P; Calzavara Pinton P; Caproni M; Alaibac M; De Simone C; Patrizi A; Cozzani E; Papini M; Tedeschi A; Berti E; Rosendaal FR;
Thromb Haemost; 2016 Jan; 115(1):193-9. PubMed ID: 26245987
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis is associated with increased risk of bullous pemphigoid: A nationwide population-based cohort study in Taiwan.
Ho YH; Hu HY; Chang YT; Li CP; Wu CY
J Dermatol; 2019 Jul; 46(7):604-609. PubMed ID: 31062428
[TBL] [Abstract][Full Text] [Related]
6. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.
Langan SM; Smeeth L; Hubbard R; Fleming KM; Smith CJ; West J
BMJ; 2008 Jul; 337(7662):a180. PubMed ID: 18614511
[TBL] [Abstract][Full Text] [Related]
7. Association of Immunosuppressants with Mortality of Patients with Bullous Pemphigoid: A Nationwide Population-Based Cohort Study.
Wu CY; Wu CY; Li CP; Lin YH; Chang YT
Dermatology; 2022; 238(2):378-385. PubMed ID: 34139703
[TBL] [Abstract][Full Text] [Related]
8. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid.
Baum S; Steinberg S; Tzanani I; Barzilai A; Lyakhovitsky A
Acta Derm Venereol; 2023 Mar; 103():adv00888. PubMed ID: 36916952
[TBL] [Abstract][Full Text] [Related]
10. Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients.
Teixeira VB; Cabral R; Brites MM; Vieira R; Figueiredo A
An Bras Dermatol; 2014; 89(2):274-8. PubMed ID: 24770504
[TBL] [Abstract][Full Text] [Related]
11. Association between bullous pemphigoid and risk of venous thromboembolism: A nationwide population-based cohort study.
Chen CL; Wu CY; Lyu YS; Chou YJ; Chang YT; Wu CY
J Dermatol; 2022 Aug; 49(8):753-761. PubMed ID: 35491650
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
[TBL] [Abstract][Full Text] [Related]
13. Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study.
Albadri Z; Thorslund K; Häbel H; Seifert O; Grönhagen C
Acta Derm Venereol; 2020 Oct; 100(17):adv00289. PubMed ID: 32852559
[TBL] [Abstract][Full Text] [Related]
14. Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients.
Thorslund K; Seifert O; Nilzén K; Grönhagen C
Arch Dermatol Res; 2017 Nov; 309(9):721-727. PubMed ID: 28875235
[TBL] [Abstract][Full Text] [Related]
15. Bullous pemphigoid and antecedent neurological diseases: An association with dementia.
Yu Phuan CZ; Yew YW; Tey HL
Indian J Dermatol Venereol Leprol; 2017; 83(4):457-461. PubMed ID: 28584223
[TBL] [Abstract][Full Text] [Related]
16. Risk of venous thromboembolism in patients with bullous pemphigoid: A systematic review and meta-analysis.
Ungprasert P; Wijarnpreecha K; Thongprayoon C
Indian J Dermatol Venereol Leprol; 2018; 84(1):22-26. PubMed ID: 29185440
[TBL] [Abstract][Full Text] [Related]
17. Risk of solid malignancies in bullous pemphigoid: A large-scale population-based cohort study.
Kridin K; Hammers CM; Ludwig RJ; Cohen AD
J Dermatol; 2021 Mar; 48(3):317-323. PubMed ID: 33368562
[TBL] [Abstract][Full Text] [Related]
18. Bullous pemphigoid: Its incidence, mortality and clinical outcome in New Zealand.
Chung JG; Ramji R; Coomarasamy C; Jarrett P; Rademaker M; Patel DC
Australas J Dermatol; 2022 May; 63(2):197-203. PubMed ID: 35324003
[TBL] [Abstract][Full Text] [Related]
19. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
[TBL] [Abstract][Full Text] [Related]
20. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample.
Ren Z; Narla S; Hsu DY; Silverberg JI
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1768-1776. PubMed ID: 29575160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
